Clinical trials: Tamoxifen
Male Breast Cancer, Stage II Breast Cancer
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
This phase II trial is studying how well giving bevacizumab together with combination chemotherapy works in treating patients who have undergone surgery for breast cancer that has spread to the lymph nodes.
- Conditions
- Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00119262
- Testing
- doxorubicin hydrochloride, cyclophosphamide, bevacizumab
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- National Cancer Institute (NCI)
Female Breast Cancer
Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer
The study is a prospective multi-center randomized control clinical trial which is sponsored by the researchers. The purpose of this study is to determine the effectiveness of adjuvant endocrine therapy for operable ER-beta…
- Trial name
- AETNBC (NCT02089854)
- Testing
- Toremifene; Anastrozole
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer Female, Hormone Receptor Positive Tumor
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer
Phase II trial of 2 years of standard adjuvant endocrine therapy after low risk hormone receptor positive, HER2 negative, node negative breast cancer in women older than 50 at diagnosis.
- Trial name
- LALEAST (NCT03917082)
- Testing
- Tamoxifen Citrate
- Where
- Canada
- Volunteers
- 290 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer, Cancer of Breast
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Multiple neoadjuvant endocrine trials demonstrate that women with good prognosis tumors can be identified. These trials have also demonstrated that there are not adverse effects on overall outcome if women are treated with…
- Conditions
- Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
- Trial name
- NCT02476786
- Testing
- FACT-B, Goserelin, Anastrozole
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Stage IIA Breast Cancer, Stage IIB Breast Cancer
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
This pilot clinical trial studies chemotherapy before surgery and tissue sample collection in patients with stage IIA-IIIC breast cancer.
- Conditions
- Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT01897441
- Testing
- Cyclophosphamide, Cytology Specimen Collection Procedure, Doxorubicin Hydrochloride
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Albert Einstein College of Medicine
Breast Cancer
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen.
- Trial name
- TEXT (NCT00066703)
- Testing
- exemestane, tamoxifen, triptorelin
- Where
- 228 sites in United States, Australia and 15 more
- Volunteers
- 2,672 people
- Sponsor
- ETOP IBCSG Partners Foundation
Melanoma (Skin)
Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00492505
- Testing
- cisplatin, sorafenib tosylate, tamoxifen citrate
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- San Diego Pacific Oncology & Hematology Associates
ER+ Breast Cancer
Tamoxifen Prediction Study in Patients With ER+ Breast Cancer
Adjuvant treatment with tamoxifen is the standard of care for women with estrogen receptor positive (ER+) breast cancer. Tamoxifen is converted to endoxifen, its active metabolite, via CYP2D6 enzymes.
- Trial name
- PREDICTAM (NCT05525481)
- Testing
- Tamoxifen
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Erasmus Medical Center
PCOS
Clomiphene Citrate Versus Tamoxifen for Ovulation Induction in PCOs
Comparison between Clomiphene citrate and Tamoxifen for induction of ovulation in women with PCOS.
- Trial name
- NCT02479256
- Testing
- Clomiphene citrate, Tamoxifen
- Where
- Egypt
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Schizophrenia, Schizoaffective Disorder
The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study
The aim of the project is to investigate the use of raloxifene (a new form of estrogen) as a treatment for schizophrenia in postmenopausal women.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00206557
- Testing
- Raloxifene, Estradiol/dyhydroprogestrone
- Where
- Australia
- Volunteers
- 60 people
- Sponsor
- The Alfred
Breast Neoplasms, Tamoxifen
CYP2D6 Genotype on the Clinical Effect of Tamoxifen
The purpose of this study is to investigate the impact of CYP2D6 Genotype on the clinical effects of tamoxifen using with samples from prospective randomized multicenter study(ASTRRA).
- Conditions
- Breast Neoplasms, Tamoxifen, Genotype, CYP2D6
- Trial name
- ASTRRA-CYP2D6 (NCT00973037)
- Testing
- Tamoxifen
- Where
- South Korea
- Volunteers
- 922 people
- Sponsor
- Korea University Anam Hospital
Breast Neoplasms
Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
To determine the safety and efficacy of LY353381 when compared to tamoxifen in women with advanced or metastatic breast cancer.
- Trial name
- NCT00034125
- Testing
- LY353381, tamoxifen
- Where
- 11 sites in United States, Argentina and 3 more
- Sponsor
- Eli Lilly and Company
Advanced, Persistent, or Recurrent Endometrial Cancer
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
The main purpose of this study is to evaluate the effectiveness of the combination of the drugs Everolimus and Letrozole compared to Tamoxifen and Medroxyprogesterone acetate in treating endometrial cancer and to determine the…
- Trial name
- NCT02228681
- Testing
- Everolimus, Tamoxifen, Letrozole
- Where
- 26 sites in United States
- Volunteers
- 74 people
- Sponsor
- GOG Foundation
Breast Cancer
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
TOL2506A (OVELIA) is a Phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 in suppressing ovarian function in premenopausal women with HR+, HER2-negative breast cancer and men with HR+ breast cancer.
- Trial name
- NCT05645536
- Testing
- TOL2506, Tamoxifen, Letrozole tablets
- Where
- 46 sites in United States, Argentina and 4 more
- Volunteers
- 250 people
- Sponsor
- Tolmar Inc.
Breast Cancer
Raloxifene in Preventing Breast Cancer in Premenopausal Women
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of raloxifene may be an effective way to prevent breast cancer in premenopausal women.
- Trial name
- NCT00019500
- Testing
- raloxifene, evaluation of cancer risk factors
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Osteoporosis
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
- Trial name
- NCT00431444
- Testing
- Raloxifene, Zoledronic acid
- Where
- 17 sites in United States
- Volunteers
- 110 people
- Sponsor
- Novartis
Vulvar Atrophy
Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA
The purpose of the study is to study the safety, PK and PD of Intravaginal Tamoxifen on postmenopausal women with vulvar vaginal atrophy.
- Trial name
- DARE-VVA1 (NCT05378269)
- Testing
- Tamoxifen
- Where
- 2 sites in Australia
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Daré Bioscience, Inc.
Metastatic Breast Cancer
A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).
The goal of the study for patients with metastatic breast cancer (MBC) is to show that palbociclib + endocrine therapy shows a significant improvement in time-to-treatment failure over chemotherapy regimen (mono-chemotherapy with…
- Trial name
- PADMA (NCT03355157)
- Testing
- Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- GBG Forschungs GmbH
Early-stage Breast Cancer, Hormone Receptor Positive Tumor
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.
A phase II randomised, open label study of pre-operative endocrine therapy with \& without prometrium in postmenopausal women with early stage breast hormone receptor positive (HR+) human epidermal receptor 2 negative (HER2-)…
- Trial name
- WinPro (NCT03906669)
- Testing
- Letrozole, Letrozole and Prometrium, Tamoxifen and Prometrium
- Where
- Australia
- Volunteers
- 200 people
- Sponsor
- St Vincent's Hospital
Metastatic Breast Cancer, Hormone Receptor Positive
A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
This phase II trial studies the side effects of palbociclib when given together with fulvestrant or tamoxifen citrate in treating patients with hormone receptor positive breast cancer that has spread from where it started to…
- Trial name
- NCT02384239
- Testing
- Palbociclib, Tamoxifen, Fulvestrant
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of California, San Francisco